Tender detail
Amgros medicines framework agreements 2027
Summary
Amgros is procuring medicines for Danish hospital pharmacies under 10 separate lots, covering infliximab, adalimumab and ustekinumab in specified strengths and infusion or injection forms. The estimated total value is DKK 1,266,300,000, with a maximum value of DKK 1,646,190,000. The framework agreements are non-exclusive and do not guarantee purchases; actual demand may differ substantially from historical consumption.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.